These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 35120612)

  • 1. Why the application of IVIG might be beneficial in patients with COVID-19 - Authors' reply.
    Mazeraud A; Wolff M; Lucas B; Sharshar T
    Lancet Respir Med; 2022 Feb; 10(2):e16. PubMed ID: 35120612
    [No Abstract]   [Full Text] [Related]  

  • 2. Why the application of IVIG might be beneficial in patients with COVID-19.
    Kindgen-Milles D; Feldt T; Jensen BEO; Dimski T; Brandenburger T
    Lancet Respir Med; 2022 Feb; 10(2):e15. PubMed ID: 35120611
    [No Abstract]   [Full Text] [Related]  

  • 3. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Autoimmun Rev; 2020 Jul; 19(7):102559. PubMed ID: 32361195
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Authors' reply.
    Pei L; Zhang S; Geng X; Li W; Chen D
    Pol Arch Intern Med; 2020 Oct; 130(10):922-923. PubMed ID: 33119226
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
    Dalakas MC; Bitzogli K; Alexopoulos H
    Front Immunol; 2021; 12():627285. PubMed ID: 33679770
    [No Abstract]   [Full Text] [Related]  

  • 6. The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia.
    Almontasheri A; Al-Husayni F; Alsuraihi AK; Binyahib H; Albanna AS
    Am J Case Rep; 2021 Feb; 22():e929447. PubMed ID: 33612712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
    Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
    Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
    Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
    Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presumed protective effect of IVIG against SARS-CoV-2 in inflammatory myopathy patients remains questionable.
    Finsterer J; Scorca FA
    Rheumatol Int; 2024 Feb; 44(2):397-398. PubMed ID: 37750895
    [No Abstract]   [Full Text] [Related]  

  • 10. Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy.
    Romozzi M; Bisogni G; Sabatelli M; Luigetti M
    Neurol Sci; 2021 Mar; 42(3):787-789. PubMed ID: 33428052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update.
    Romero C; Díez JM; Gajardo R
    Lancet Infect Dis; 2022 Jan; 22(1):19. PubMed ID: 34953544
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.
    Raman RS; Bhagwan Barge V; Anil Kumar D; Dandu H; Rakesh Kartha R; Bafna V; Aravinda VT; Raghuram TC
    J Infect Dis; 2021 May; 223(9):1538-1543. PubMed ID: 33585890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiety among the parents of pediatric patients receiving IVIG therapy during the Covid-19 pandemic.
    Topal ÖY; Metin A; Çöp E; Dinç GŞ; Üneri ÖŞ
    Turk J Pediatr; 2021; 63(5):801-810. PubMed ID: 34738362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin therapy in COVID-19-related encephalopathy.
    Muccioli L; Pensato U; Bernabè G; Ferri L; Tappatà M; Volpi L; Cani I; Henry OJ; Ceccaroni F; Cevoli S; Stofella G; Pasini E; Fornaro G; Tonon C; Vidale S; Liguori R; Tinuper P; Michelucci R; Cortelli P; Bisulli F
    J Neurol; 2021 Aug; 268(8):2671-2675. PubMed ID: 33030607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and TEN Treated With IVIG and Total Plasma Exchange: Simultaneous Systemic Treatment for Both Diseases.
    Krajewski A; Mlynska-Krajewska E; Kaczynska K; Strużyna J; Mazurek MJ
    J Investig Allergol Clin Immunol; 2021 Dec; 31(6):522-523. PubMed ID: 33847265
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool.
    Tzilas V; Manali E; Papiris S; Bouros D
    Respiration; 2020; 99(12):1087-1089. PubMed ID: 33212437
    [No Abstract]   [Full Text] [Related]  

  • 17. Unclear conclusions on SARS-CoV-2 elimination versus mitigation - Authors' reply.
    Oliu-Barton M; Pradelski BSR; Aghion P; Artus P; Kickbusch I; Lazarus JV; Vanderslott S
    Lancet; 2021 Oct; 398(10311):1566-1567. PubMed ID: 34755623
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 and electrocardiography: is electrocardiography a predictor of mortality?-Authors' reply.
    Lanza GA; De Vita A
    Europace; 2021 Jul; 23(7):1151. PubMed ID: 34077534
    [No Abstract]   [Full Text] [Related]  

  • 19. Stability of SARS-CoV-2 in different environmental conditions - Authors' reply.
    Chin AWH; Poon LLM
    Lancet Microbe; 2020 Aug; 1(4):e146. PubMed ID: 33521712
    [No Abstract]   [Full Text] [Related]  

  • 20. Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches.
    Stinca S; Barnes TW; Vogel P; Meyers W; Schulte-Pelkum J; Filchtinski D; Steller L; Hauser T; Manni S; Gardiner DF; Popik S; Roth NJ; Schuetz P
    PLoS One; 2021; 16(11):e0259731. PubMed ID: 34843493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.